Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1819479 in Healthy Male Subjects
NCT04801693Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI1819479 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Percentage of subjects with drug-related adverse events, Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point and 1 more. Started May 2021; status: completed.
02
Drugs
BI1819479
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04801693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04801693.